Annexon (ANNX) financial statements

Healthcare · Biotechnology · Market cap $630M

Net income was -$207M.

Free cash flow was -$186M.

The diluted share count rose 35680% over the period (dilution).

Income statement

Fiscal years, from Annexon's 10-K filings with the SEC.

Fiscal year2019202020212022202320242025
Research and development$25M$49M$100M$113M$114M$119M$185M
Selling, general and admin$8M$14M$31M$33M$30M$35M$32M
Operating income-$33M-$63M-$131M-$146M-$144M-$154M-$216M
Pre-tax income-$37M-$63M$130M$142M$134M-$138M-$207M
Income tax$4,000——$0$0$0$0
Net income-$37M-$63M-$130M-$142M-$134M-$138M-$207M
EPS (diluted)-$88.30-$4.15-$3.40-$2.60-$1.77-$1.01-$1.34
Diluted shares0M17M38M55M76M137M155M

Balance sheet

Fiscal years, from Annexon's 10-K filings with the SEC.

Fiscal year2019202020212022202320242025
Cash and short-term investments$44M$351M$243M$243M$260M$312M$238M
Total current assets$45M$354M$248M$248M$264M$316M$242M
Property, plant and equipment$2M$2M$18M$17M$15M$13M$11M
Total assets$50M$356M$287M$285M$298M$350M$278M
Total current liabilities$5M$11M$22M$22M$18M$31M$43M
Total liabilities$6M$12M$55M$54M$47M$57M$66M
Shareholders' equity-$100M$344M$232M$231M$251M$293M$212M
Net debt-$44M-$269M-$75M-$140M-$225M-$49M-$162M

Cash flow

Fiscal years, from Annexon's 10-K filings with the SEC.

Fiscal year2019202020212022202320242025
Operating cash flow-$28M-$53M-$106M-$116M-$121M-$118M-$186M
Capital spending$267,000$464,000$2M$7M$193,000$15,000$137,000
Free cash flow-$29M-$54M-$108M-$123M-$121M-$118M-$186M
Stock-based compensation$2M$5M$16M$19M$18M$19M$16M
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANNX.
Open ANNX in Investingly

Questions

How much free cash flow does Annexon generate?

-$186M in fiscal 2025 (operating cash flow minus capital spending).

From Annexon's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.